CN101239167B - Medicaments for treating hysteromyoma - Google Patents
Medicaments for treating hysteromyoma Download PDFInfo
- Publication number
- CN101239167B CN101239167B CN2008100144943A CN200810014494A CN101239167B CN 101239167 B CN101239167 B CN 101239167B CN 2008100144943 A CN2008100144943 A CN 2008100144943A CN 200810014494 A CN200810014494 A CN 200810014494A CN 101239167 B CN101239167 B CN 101239167B
- Authority
- CN
- China
- Prior art keywords
- medicine
- radix
- hysteromyoma
- treatment
- volatile oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a medicine for treating hysteromyoma and a method for preparing the same. The medicine is prepared from raw materials by weight rate including 10-20g thunberg fritillary bulb, 10-20g schisandra chinensis, 10-20g bupleurum, 10-20g turmeric root-tuber, 10-20g angelica, 3-10g uniflower swisscentaury root, 3-10g nutgrass galingale rhizome, 3-10g glossy ganoderma, 3-10g panax notoginseng, 3-10g xuetong, 3-10g red paeony root. The preparing method includes steps as follows: combining with angelica, nutgrass galingale rhizome, bupleurum, turmeric root-tuber, then extracting volatile oil; combining with other medicine and the herb residue, boiling two times with water and two hours each time, combining and decocting solution, then filtering, the filter liquid is condensed to relative density 1.04-1.05, standing, and oblique taking the upper clear liquid, then filtering, the filter liquid is continuous condensed to relative density 1.08-1.10, adding said volatile oil and mixing; filling to bottle and sterilization with cobalt 60. The medicine has merits of better treating effect, fast effect, little toxic side effect, rapid recovery, non-wound and easy processing method.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of hysteromyoma, particularly a kind of medicine of the treatment hysteromyoma of making by pure Chinese medicine, and manufacturing method for above mentioned medicine.
Background technology
Hysteromyoma is as a kind of gynaecopathia, and its sickness rate has trend of rising gradually, has had a strong impact on women's physical and mental health
General both at home and abroad at present employing excision is treated, and operative treatment has caused local failure to the human body whole organ, and has increased patient's misery and financial burden, can not unavoidably can produce sequela after the operation.As Drug therapy, its therapeutic effect is undesirable, and Time of Administration is long cumbersome.
Summary of the invention
The object of the present invention is to provide a kind ofly have that therapeutic effect is good, the medicine of instant effect, treatment hysteromyoma that toxic and side effects is little.
Another object of the present invention is to provide manufacturing method for above mentioned medicine.
Purpose of the present invention is realizing by following measure:
The present invention relates to a kind of medicine for the treatment of hysteromyoma, form: Bulbus Fritillariae Thunbergii 10-20g, Fructus Schisandrae Chinensis 10-20g, Radix Bupleuri 10-20g, Radix Curcumae 10-20g, Radix Angelicae Sinensis 10-20g, Radix Rhapontici 3-10g, Rhizoma Cyperi 3-10g, Ganoderma 3-10g, Radix Notoginseng 3-10g, blood logical 3-10g, Radix Paeoniae Rubra 3-10g by following materials of weight proportions medicine.
The medicine of the treatment hysteromyoma of the invention described above, the optimum weight proportioning of described medicine is: Bulbus Fritillariae Thunbergii 15g, Fructus Schisandrae Chinensis 15g, Radix Bupleuri 15g, Radix Curcumae 15g, Radix Angelicae Sinensis 15g, Radix Rhapontici 8g, Rhizoma Cyperi 8g, Ganoderma 8g, Radix Notoginseng 8g, blood logical 8g, Radix Paeoniae Rubra 8g.
The preparation method of the medicine of the treatment hysteromyoma of the invention described above, adopt following steps:
(1) Radix Angelicae Sinensis, Rhizoma Cyperi, Radix Bupleuri, Radix Curcumae merge, and extract volatile oil;
(2) medicinal residues behind the extraction volatile oil and medicinal liquid and remaining medicine merge, decoct with water secondary, each 2 hours, collecting decoction, filter, it is 1.04～1.05 that filtrate is concentrated into relative density, leaves standstill, and inclines and gets supernatant, filter, it is 1.08～1.10 that filtrate continuation is concentrated into relative density, adds above-mentioned volatile oil, mixing;
(3) bottling, cobalt 60 sterilizations.
Beneficial effect of the present invention: therapeutic effect is good, instant effect, toxic and side effects is little, the patient recovers soon, no operation wound, and preparation method is simple to operation.
The medicine that the present invention treats hysteromyoma shows that through the several animal models experiment its action effect is remarkable, and division is as follows:
1. long term toxicity test
With the Sprague-Dawley rat medicine of the present invention is carried out long term toxicity test, (calculate with 60g crude drug/kg and two dosage of 30g crude drug/kg by kg body weight, 20 times and 10 times of clinical consumption per day are equivalent to respectively to be grown up) give rat successive administration 4 months, to observe the toxicity size.Experimental result finds that this medicine there is no remarkable toxic action to behavioral activity, fur, feed drinking-water, defecation, growth promoter, hemogram (routine blood test and cell divide inspection), liver function, the renal function of animal.
When diagnosis finishes, get the rat heart, liver, spleen, lung, kidney, adrenal gland, ovary, uterus and do perusal, fix specimens paraffin embedding slices with Formalin, the HE chromoscopy, the result shows that two dosetests are compared with the blank group and does not see obvious pathological change.
The result show the present invention treat the poisonous side effect of medicine of hysteromyoma little, in clinical using dosage scope, be safe.
2. to the influence of estrogen induced mice uterus weight
With the method for sc estradiol, preparation Mouse Uterus weightening finish model.The medicine of treatment hysteromyoma is given the female mice administration with basic, normal, high serial dosage, gavage 30 days continuously, experimental result is relatively treated dosage group in the medicine of hysteromyoma, and ((the 30g crude drug/kg) Mouse Uterus coefficient ratio model control group obviously reduces for 15g crude drug/kg) and high dose group.Show that the medicine for the treatment of hysteromyoma has certain inhibitory action to estrogen induced mice uterus weight.
3. to the influence of thymus and spleen weight
Levamisole medicine is in contrast selected in this experiment for use.
Get 50 of 12-20g female mices, be divided into 5 groups at random, 10 every group, irritate capacity NS such as stomach respectively, irritate medicine 10g crude drug/kg of the present invention; Lumbar injection CTX0.03g/kg also uses medicine 10g crude drug/kg of the present invention; Irritate stomach levamisole 0.2g/kg; Lumbar injection CTX0.03g/kg also uses levamisole 0.2g/kg; Continuous 10 days.Put to death animal in 24 hours after the last administration, take out thymus and spleen and weigh, calculate thymus and spleen index (mg weight/g body weight).The result shows that medicine of the present invention causes the immunologic hypofunction mouse thymus to CTX and spleen weight has obvious potentiation, sees Table 1.
Table 1 medicine of the present invention is to thymus, spleen weight and anti-immunosuppressive action
| Group | Dosage | Thymus index | Index and spleen index |
| NS | Deng capacity | 3.78±0.82 | 5.24±1.26 |
| Medicine of the present invention | 10 | 3.85±0.84 | 5.64±1.52 |
| CTX+ medicine of the present invention | 0.03+10 | 4.82±0.72△ | 3.85±0.86△ |
| Levamisole | 0.2 | 4.6±80.48※ | 6.72±0.97※ |
| The CTX+ levamisole | 0.03+0.2 | 3.92±0.88△ | 4.30±1.00△ |
N=10, X ± SD compares ※ P＜0.05 with NS, compare △ P＜0.01 with CTX.
4. to rat endocrine level affects
This experiment continuously to the medicine of rat treatment hysteromyoma 35 days, is observed the influence of medicine to female rats endocrine level.Experimental result shows that after the medicine of treatment hysteromyoma was low, Senior Two dosage is taken medicine continuously, the intravital estradiol of rat, progesterone, lutropin, corticosterone blood plasma level compared with blank group, do not see remarkable shape difference.
5. anti-anemia effect
This experiment adopts the blood-letting of mouse tail blood vessel to prepare the chmice acute model of losing blood, and gives the medicine 10 days of treatment hysteromyoma, HB amount of middle and high dosage group mice and RBC number than blood-letting after obviously rising, show that this medicine has certain anti-anemia effect.
6. to the microcirculatory influence in uterus
Get 30 of rat, be divided into 5 groups at random, normal control group, high, medium and low concentration drug test group of the present invention and FUFANG DANSHEN ZHUSHEYE group.An Aconitum carmichaeli Debx. palace and a ligament taken out in rat anesthesia back, be fixed in the temperature chamber of containing normal saline, stablize 30min, with tape measure arteriole and thin vein bore.Observe the blood fluidised form by standard again, the results are shown in Table 2.
Medicine of the present invention is to the uterus microcirculation
| Group | Concentration g/g | Caliber | The blood fluidised form |
| The NS matched group | - | 24.8±2.68 | Grain is slow |
| Low concentration group | 2 | 60.1±6.82※ | The grain line |
| Middle concentration group | 4 | 68.8±6.12※ | The grain line |
| The high concentration group | 6 | 76.8±4.35※ | The grain line |
| The FUFANG DANSHEN ZHUSHEYE group | 2 | 75.4±3.58※ | The grain line |
Compare ※ P＜0.001 with the NS group
Experimental result shows that the medicine of treatment treatment hysteromyoma can make uterus microcirculatory vascular expansion, and blood flow increases, and has reduced hemocyte gathering, sticking wall, prevents that the blood flow stasis of blood from stagnating.
7. antiinflammatory action
The medicine of this laboratory observation treatment hysteromyoma brings out the Mice Auricle edema to mice capillary permeability, xylol and Ovum Gallus domesticus album is caused the influence of the toes swelling of rat.Experimental result shows that the medicine of treatment hysteromyoma can reduce the mice capillary permeability, and minimizing is oozed out; Xylol brings out the Mice Auricle edema and Ovum Gallus domesticus album is caused that the toes swelling of rat has certain inhibitory action.
8. to the influence of rat endocrine level
This experiment gives the medicine 32 days of rat treatment hysteromyoma continuously, observes the influence of medicine to rat endocrine level.Experimental result shows, behind low, the Senior Two dosage group continuous use of medicine of treatment hysteromyoma, the intravital estradiol of rat (E2), progesterone (P), lutropin (LH) and corticosterone blood plasma level and normal control group are relatively, do not see significant difference, show that the medicine for the treatment of hysteromyoma does not have obvious influence to the estrogen of laboratory animal with relevant endocrine hormone level.
The 200 routine clinical observations of treatment hysteromyoma:
1. clinical data
(1) object of observation: the inconvenience persons of undergoing surgery such as menorrhagia or menostaxis, anemia, hypertension, heart disease; The very big body constitution of older, tumor is than weak person; Age is at 25-49 between year, 35 years old mean age; The course of disease is the shortest 3 months, and is the longest 12 years.
(2) efficacy assessment standard
" produce effects ": after treatment, cardinal symptom all disappears, clinical cure (B ultrasonic check tumor body disappears).
" effectively ": muscular tumor reduces or dwindles, and symptom takes a turn for the better than treatment is preceding.
" invalid ": the clinical symptoms sign does not have improvement, muscular tumor and the preceding no significant change of treatment.
(4) therapeutic effect:
Clinical muscular tumor disappearance produce effects 85 examples account for 42.5%; Muscular tumor reduces or dwindles effective 49 examples, and metrorrhagia, effective 35 examples of leaking down to take a turn for the better, dysmenorrhea effective 16 examples that take a turn for the better account for 50%; Invalid 15 examples account for 7.5%.
2. clinical verification is for example:
1) poplar * *, the woman, 40 years old, be diagnosed as multiple myomata through B ultrasonic in 96 years, to treat after 2 months, menstrual onset is normal.Treated again 1 month after ultrasound diagnosis, muscular tumor reduces one, other volume-diminished, after treated again 6 months, through the B ultrasonic check, hysteromyoma complete obiteration, recurrence so far.
2) open * *, the woman, 30 years old, menoxenia at ordinary times, menstruation fell behind 4-6 days, and hysteromyoma is found in ultrasound diagnosis, medication 7 days, vagina is discharged tissue substance, and ultrasound diagnosis uterus and adnexa are no abnormal after taking medicine one month, and menstruation is also normal.
3) Song * *, the woman, 25 years old, metrorrhagia is arranged, leak down, lack symptoms such as eating insomnia, obey medicine of the present invention, recovery from illness in 5 days.
4) Liu * *, the woman, 38 years old, be diagnosed as through B ultrasonic and contain 1.5 * 2 to more than 3 * 4 hysteromyoma, obey medicine of the present invention after one month hysteromyoma stop growing, dwindle hysteromyoma disappearance after 168 days through three months treatment back hysteromyoma.
The specific embodiment
Embodiment 1:
The medicine of the treatment hysteromyoma of present embodiment, the weight proportion of described medicine is: Bulbus Fritillariae Thunbergii 15kg, Fructus Schisandrae Chinensis 15kg, Radix Bupleuri 15kg, Radix Curcumae 15kg, Radix Angelicae Sinensis 15kg, Radix Rhapontici 8kg, Rhizoma Cyperi 8kg, Ganoderma 8kg, Radix Notoginseng 8kg, blood logical 8kg, Radix Paeoniae Rubra 8kg.
Its preparation method is: get Radix Angelicae Sinensis, Rhizoma Cyperi, Radix Bupleuri, Radix Curcumae merging, extract volatile oil; Medicinal residues behind the extraction volatile oil and medicinal liquid and all the other 7 herbal medicines merge, decoct with water secondary, each 2 hours, collecting decoction, filter, it is 1.04～1.05 that filtrate is concentrated into relative density, leaves standstill, and inclines and gets supernatant, filter, it is 1.08～1.10 that filtrate continuation is concentrated into relative density, adds above-mentioned volatile oil, mixing; Bottling, oral formulations is made in cobalt 60 sterilizations.
Usage and consumption: oral, every day three times, each 5 milliliters.
Embodiment 2:
The medicine of the treatment hysteromyoma of present embodiment, the weight proportion of described medicine is: Bulbus Fritillariae Thunbergii 20kg, Fructus Schisandrae Chinensis 15kg, Radix Bupleuri 20kg, Radix Curcumae 10kg, Radix Angelicae Sinensis 10kg, Radix Rhapontici 10kg, Rhizoma Cyperi 10kg, Ganoderma 5kg, Radix Notoginseng 5kg, blood logical 3kg, Radix Paeoniae Rubra 3kg.
Its preparation method is: get Radix Angelicae Sinensis, Rhizoma Cyperi, Radix Bupleuri, Radix Curcumae merging, extract volatile oil, volatile oil coats with beta-schardinger dextrin-; Medicinal residues behind the extraction volatile oil and medicinal liquid and all the other 7 herbal medicines merge, and decoct with water secondary, and each 2 hours, collecting decoction filtered, and it is 1.04～1.05 that filtrate is concentrated into relative density, leaves standstill, and inclines and gets supernatant, filters, and filtrate continuation is concentrated into clear paste; Volatile oil after the beta-schardinger dextrin-coating is mixed with clear paste, add a certain amount of adjuvant, make granule.
Usage and consumption: oral, every day three times, each 10-2g.
Embodiment 3:
The medicine of the treatment hysteromyoma of present embodiment, the weight proportion of described medicine is: Bulbus Fritillariae Thunbergii 15kg, Fructus Schisandrae Chinensis 20kg, Radix Bupleuri 15kg, Radix Curcumae 20kg, Radix Angelicae Sinensis 20kg, Radix Rhapontici 3kg, Rhizoma Cyperi 3kg, Ganoderma 10kg, Radix Notoginseng 3kg, blood logical 10kg, Radix Paeoniae Rubra 10kg.
Its preparation method is: get Radix Angelicae Sinensis, Rhizoma Cyperi, Radix Bupleuri, Radix Curcumae merging, extract volatile oil, volatile oil coats with beta-schardinger dextrin-; Medicinal residues behind the extraction volatile oil and medicinal liquid and all the other 7 herbal medicines merge, and decoct with water secondary, and each 2 hours, collecting decoction filtered, and it is 1.04～1.05 that filtrate is concentrated into relative density, leaves standstill, and inclines and gets supernatant, filters, and filtrate continuation is concentrated into clear paste; Volatile oil after the beta-schardinger dextrin-coating is mixed with clear paste, add a certain amount of adjuvant, make tablet, the 0.3g/ sheet.
Usage and consumption: oral, every day three times, each 3-5g.
Claims (2)
1. medicine for the treatment of hysteromyoma, it is characterized in that: the crude drug of described medicine consists of: Bulbus Fritillariae Thunbergii 10-20g, Fructus Schisandrae Chinensis 10-20g, Radix Bupleuri 10-20g, Radix Curcumae 10-20g, Radix Angelicae Sinensis 10-20g, Radix Rhapontici 3-10g, Rhizoma Cyperi 3-10g, Ganoderma 3-10g, Radix Notoginseng 3-10g, blood logical 3-10g, Radix Paeoniae Rubra 3-10g.
2. the medicine of treatment hysteromyoma according to claim 1 is characterized in that: the weight proportion of described crude drug is: Bulbus Fritillariae Thunbergii 15g, Fructus Schisandrae Chinensis 15g, Radix Bupleuri 15g, Radix Curcumae 15g, Radix Angelicae Sinensis 15g, Radix Rhapontici 8g, Rhizoma Cyperi 8g, Ganoderma 8g, Radix Notoginseng 8g, blood logical 8g, Radix Paeoniae Rubra 8g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100144943A CN101239167B (en) | 2008-03-17 | 2008-03-17 | Medicaments for treating hysteromyoma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100144943A CN101239167B (en) | 2008-03-17 | 2008-03-17 | Medicaments for treating hysteromyoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101239167A CN101239167A (en) | 2008-08-13 |
| CN101239167B true CN101239167B (en) | 2010-09-29 |
Family
ID=39931177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008100144943A Expired - Fee Related CN101239167B (en) | 2008-03-17 | 2008-03-17 | Medicaments for treating hysteromyoma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101239167B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104258162A (en) * | 2014-10-17 | 2015-01-07 | 李正梅 | Traditional Chinese medicine composition for treating uterine myoma as well as preparation method and application of composition |
-
2008
- 2008-03-17 CN CN2008100144943A patent/CN101239167B/en not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| 林倩雯，莫蕙，郑其昌.子宫肌瘤的中医治疗概况.辽宁中医药大学学报第9卷 第5期.2007,第9卷(第5期),62-63. |
| 林倩雯,莫蕙,郑其昌.子宫肌瘤的中医治疗概况.辽宁中医药大学学报第9卷 第5期.2007,第9卷(第5期),62-63. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101239167A (en) | 2008-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102764339B (en) | Maca composition for improving sexual dysfunction and preparation method and application thereof | |
| CN104491740A (en) | Traditional Chinese medicine composition for treating liver cancer and preparation method of traditional Chinese medicine composition | |
| CN101564486A (en) | Medicament for preventing and treating ruminant post-natal diseases and preparation method thereof | |
| CN102078569A (en) | Traditional Chinese medicine preparation for treating liver cancer and preparation method thereof | |
| CN104524071A (en) | Pharmaceutical composition for treating primary renal disease and application thereof | |
| CN110478452B (en) | Traditional Chinese medicine composition for treating gout and preparation method thereof | |
| CN104524106A (en) | Traditional Chinese medicine preparation for treating prostatitis and prostatic hyperplasia and preparation method thereof | |
| CN101804126A (en) | Application of traditional Chinese medicine composition in treating qi-blood deficiency and spleen-kidney deficiency and preparation method thereof | |
| CN104173950A (en) | Chinese herbal medicine composition for treating prostatic cancer | |
| CN101129974A (en) | Traditional Chinese medicine composition for treating hepatopathy and method of preparing the same | |
| CN100548363C (en) | Medicine of treatment benign prostate hyperplasia and preparation method thereof | |
| CN104547798A (en) | Traditional Chinese medicine preparation for treating chronic enteritis and appendicitis and preparation method thereof | |
| CN104547902A (en) | Application of traditional Chinese preparation in preparation of drugs used for treating chronic enteritis and appendicitis | |
| CN101239167B (en) | Medicaments for treating hysteromyoma | |
| CN105250556A (en) | Traditional Chinese medicine drug for treating polycystic ovarian syndrome | |
| CN103845450A (en) | Application of hawthorns in preparing medicine for treating hyperuricemia, gout and renal insufficiency | |
| CN105233078A (en) | Traditional Chinese medicine composition for treating viral hepatitis | |
| CN104352994A (en) | Pharmaceutical preparation for sexual dysfunction | |
| CN104491677A (en) | Preparation method of medicament for treating sexual dysfunction | |
| CN109876127A (en) | A kind of blood-nourishing angelica capsules and preparation method thereof | |
| CN107898972A (en) | A kind of Chinese medicine composition and application for being used to treat liver diseases | |
| CN101693096A (en) | Medicament for treating liver cancer and preparation method thereof | |
| CN101690794B (en) | Antitumor medicament, preparation method and quality control method | |
| CN105106798A (en) | Traditional Chinese medicine composition for preventing and treating ovarian cancer and preparation method thereof | |
| CN105833181A (en) | Traditional Chinese medicine composition for treating chronic pelvic inflammatory disease and preparing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Cui Guoming Inventor before: Zhao Jing |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: ZHAO JING TO: CUI GUOMING |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100929 Termination date: 20110317 |